SAB Biotherapeutics (SABS) Receivables - Accured (2024 - 2026)

SAB Biotherapeutics (SABS) has 3 years of Receivables - Accured data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Receivables - Accured rose 7381.53% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 7381.53% YoY) and the FY2025 annual result came in at $946781.0, up 1622.83% from the prior year.
• Receivables - Accured improved to $1.6 million in Q1 2026, from $946781.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $1.6 million in Q1 2026 to a low of $21386.0 in Q1 2025.
• A 3-year average of $462294.4 and a median of $209116.0 in 2024 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2025 — Receivables - Accured tumbled 88.93% — and 2026, when it surged 7381.53%.
• Tracing SABS's Receivables - Accured over 3 years: stood at $54955.0 in 2024, then soared by 1622.83% to $946781.0 in 2025, then surged by 68.99% to $1.6 million in 2026.
• The last three Receivables - Accured figures came in at $1.6 million (Q1 2026), $946781.0 (Q4 2025), and $559954.0 (Q3 2025), per Business Quant data.